VIVUS (VVUS) Sinks on Conference Call; 30% of Qsymia Scipts Abandoned Due to Cash Outlay

November 6, 2012 9:25 AM EST Send to a Friend
VIVUS (Nasdaq: VVUS) continues to sink following comments on its quarterly conference call Tuesday morning.

The following are a few key pieces from VIVUS conference call:
  • 3,504 patients are on Qsymia to date;
  • Average price for 1-month supply is $160, with 20 percent reimbursement coverage since launch; and
  • About 30 percent of Qsymia prescriptions are abandoned due to cash outlay.

VIVUS is now down 10 percent, after being up 4 percent or so immediately following third-quarter results. For more, click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Conference Calls

Related Entities

Earnings

Add Your Comment